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1. Introduction 
1.1 Normal wound healing  
Wound healing is a complex and dynamic process that requires the coordinated completion 
of a variety of cellular activities, including phagocytosis, chemotaxis, mitogenesis, and 
synthesis of components of the extracellular matrix. These activities occur in a cascade that 
correlates with the appearance of multiple cell types and is regulated by soluble mediators 
such as growth factors and cytokines. In the wound healing process, three phases can be 
recognized: hemostasis and inflammation, proliferation, and tissue remodeling. These three 
phases are distinct but overlap in time (Singer and Clark 1999; Diegelmann and Evans 2004; 
Broughton, Janis et al. 2006).  
1.2 Hemostasis and inflammation  
Hemostasis and inflammation occur immediately after tissue injury. They prevent ongoing 
blood and fluid loss and establish an immune barrier against invading micro-organisms. 
Hemostasis is achieved by vasoconstriction and blood clotting. Platelets initiate the clotting 
cascade, initially by forming a platelet plug. This platelet plug is followed by a fibrin clot, 
which provides a provisional matrix scaffold for cell migration. Platelets also secrete a 
variety of growth factors and cytokines such as fibroblast growth factor (FGF), epidermal 
growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor 
beta (TGF-β), vascular endothelial growth factor (VEGF) and epidermal growth factor 
(EGF). These growth factors are located in the fibrin clot and act as promoters in the wound 
healing process by recruiting inflammatory cells to the wound site and initiating 
angiogenesis (Martin 1997).  
Once the bleeding is controlled, inflammatory cells migrate into the wound area. This is the 
start of the inflammatory phase, which is characterized by the sequential infiltration of 
neutrophils, macrophages, and lymphocytes (Broughton, Janis et al. 2006).  
Neutrophils are recruited to the wound site within 24-36 h after wounding. They are 
attracted by the growth factors released by degranulating platelets and by the products of 
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complement activation and bacteria degradation (Gurtner, Werner et al. 2008). Infiltrating 
neutrophils phagocytose contaminating bacteria and release pro-inflammatory cytokines to 
activate local fibroblasts and keratinocytes (Hubner, Brauchle et al. 1996). Within a few days 
after injury, neutrophils are extruded as eschar or as a result of apoptosis and finally are 
replaced by macrophages (Witte and Barbul 1997).  
Macrophages migrate into the wound within two or four days after injury and become the 
predominant cell type. Macrophages are derived from blood monocytes and act as the 
“orchestra conductor“ of wound healing (Lawrence and Diegelmann 1994). In the early 
stages of wound healing, macrophages phagocytose the remaining debris, bacteria, and 
apoptotic cells, including neutrophils, thus paving the way for the resolution of 
inflammation (Guo and Dipietro 2010). Macrophages also secrete a battery of cytokines (e.g., 
tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), and IL-6), growth factors (e.g., 
VEGF, FGF, PDGF,TGF-β, and EGF), and different types of metalloproteinases that degrade 
the collagen matrix (Henry and Garner 2003). This way macrophages influence cellular 
recruitment, cellular activation, angiogenesis, fibroplasia and also regulate the synthesis and 
formation of the provisional extracellular matrix, which serves as a scaffold for dermal 
regeneration and epidermal proliferation.  
Subsequently, T-lymphocytes enter the wound area and peak during the late-
proliferative/early remodeling phage. T-lymphocytes likely are involved in controlling the 
proliferation phase of wound healing. However, their exact role is not completely 
understood and is a current area of intensive investigation (Broughton, Janis et al. 2006; Guo 
and Dipietro 2010). 
1.3 Proliferation  
The proliferation phase follows and partly overlaps the inflammatory phase. The 
proliferation phase starts on the third day after injury and lasts for about 2-4 weeks. This 
phase is characterized by epithelial proliferation and migration over a provisional matrix 
within the wound (reepithelialization), fibroblast migration, and formation of granulation 
tissue. With the progression of proliferation, the provisional fibrin/fibronectin based 
provisional matrix is replaced by newly formed granulation tissue (Broughton, Janis et al. 
2006; Velnar, Bailey et al. 2009).  
1.3.1 Reepithelialization  
Reepithelialization of the wound area starts within hours after injury. Epidermal cells at the 
wound margin undergo a marked phenotypic alteration and begin to migrate into the 
wound area (Paladini, Takahashi et al. 1996). Migrating epidermal cells dissect under the 
fibrin clot across the wound, separating the desiccated eschar from viable tissue. Epidermal 
cells behind the leading migrating edge proliferate, mature and finally restore the barrier 
function of the epithelium. The stimulus for the migration and proliferation of epidermal 
cells during reepithelialization has not been clearly determined, but several possibilities are 
well documented. The absence of neighbor cells at the margin of wound (i.e., the “free edge” 
effect) may induce both migration and proliferation of epidermal cells. Local release of 
growth factors and cytokines also stimulate these processes. The initial stimulus for 
proliferation and migration of epidermal cells includes the action of EGF, TGF-α, IL-1 and 
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TNF-α, which are released by activated platelets and/or macrophages (Grotendorst, Soma 
et al. 1989; Lawrence and Diegelmann 1994). Keratinocyte growth factors (KGFs) and IL-6, 
which are released by fibroblasts, play a role in attracting neighboring keratinocytes to 
migrate, proliferate, and differentiate into epithelium (Smola, Thiekotter et al. 1993; Xia, 
Zhao et al. 1999).  
1.3.2 Fibroblast migration 
Fibroblast migration occurs two to four days after injury. Fibroblasts are attracted to the 
wound area by a number of factors, such as PDGF and TGF-β (Goldman 2004), and 
dominate the wound cell population in the first week. Within the wound area, fibroblasts 
proliferate and produce multiple structural molecules, including fibrin, fibronectin, 
glycosaminoglycans (GAGs), later followed by collagen (Witte and Barbul 1997; Robson, 
Steed et al. 2001; Ramasastry 2005). Together, these components construct the 
fibrin/fibronectin based provisional matrix (Clark, Lanigan et al. 1982), which contributes to 
the formation of granulation tissue.  
1.3.3 Granulation tissue formation  
Granulation tissue formation starts three to five days after injury and is characterized by 
angiogenesis. The numerous angiogenic factors that are secreted during the hemostatic 
phase, such as FGF, VEGF, TGF-β, and PDGF, promote angiogenesis (Servold 1991).  Four 
steps can be recognized in this process: (1) proteolytic degradation of the basement 
membrane of the parent vessels, allowing the formation of “capillary sprouts”; (2) migration 
of the endothelial cells towards the angiogenic stimulus; (3) proliferation; (4) maturation and  
remodeling of endothelial cells into capillary tubes  (Velnar, Bailey et al. 2009). Capillary 
sprouts invade the fibrin/fibronectin based provisional matrix within a few days and 
organize into a dense microvascular network. This is so called vascularized stroma, together 
with macrophages and proliferating fibroblasts, constitute the acute granulation tissue that 
replaces the fibrin/fibronectin based provisional matrix (Witte and Barbul 1997; Baum and 
Arpey 2005). With collagen accumulation, angiogenesis ceases and the density of the 
microvascular network diminishes. When homeostasis between collagen synthesis and 
degradation is achieved, tissue remodeling begins. 
1.4 Tissue remodeling  
Tissue remodeling phase is the final phase of wound healing. It starts one week after 
injury and lasts over a year or more. The main feature of this phase is the deposition of 
collagen in an organized network. During this phase, all short term events that were 
activated after injury cease: most macrophages, endothelial cells, fibroblasts, and 
myofibroblasts undergo apoptosis or exit from the wound. They leave a mass that consists 
mostly of collagen and other matrix proteins. Without an increase in collagen content, this 
largely acellular matrix subsequently is reorganized from a disorganized, mainly type III 
collagen fibers containing temporary matrix, into a lattice structure which is 
predominantly composed of type I collagen (Madden and Peacock 1968; Gurtner, Werner 
et al. 2008). A process that is dependent on collagen synthesis, which in part is the net 
result of the interaction between matrix metalloproteinases and tissue inhibitors of 
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metalloproteinases (Madlener, Parks et al. 1998). During this phase, the wound 
progressively continues to increase in tensile strength. Nevertheless, wounds never regain 
the original strength. At maximal strength, healed wounds are 80% as strong as normal 
skin (Madden and Peacock 1968). 
2. Impaired wound healing  
Impaired healing wounds generally failed to progress through the normal stages of wound 
healing. Impaired healing wounds can be arrested in any of the different healing stages, 
however, frequently enter a state of pathologic inflammation. As a result, the wounds 
cannot be repaired in an orderly and timely manner, subsequently resulting in poor 
anatomical and functional outcome (Lazarus, Cooper et al. 1994). Both acute wounds and 
chronic wounds can exhibit impaired healing. 
2.1 Factors affecting wound healing  
Wound healing can be impaired by multiple factors in any of the healing phases. These 
factors are categorized into local and systemic factors. Local factors are those that directly 
influence the characteristics of the wound. Systemic factors concern the overall health or 
disease state of the individual which affects the ability to heal (Table 1). However, these 
factors often are interrelated so their influences are not mutually exclusive. Single or 
multiple factors may, therefore, play a role in any one or more individual phases, 
contributing to the overall outcome of the healing process (Guo and Dipietro 2010).  
 
Local Factors Systemic Factors 
Infection 
Tissue maceration 
Foreign bodies 
Ischemia 
Venous insufficiency 
Desiccation 
Necrosis 
Pressure 
Trauma 
Edema 
Local cancer 
Radiation 
Toxins 
Iatrogenic factors 
Age 
Sex hormones 
Obesity 
Stress 
Diseases: diabetes , artery disease, peripheral vascular disease 
Immunocompromised conditions: AIDS, radiation therapy,   
chemotherapy  
Congenital healing disorders: epidermolysis bullosa, Ehlers-
Danlos syndrome, Marfan’s syndrome 
Alcoholism 
Smoking 
Distant cancer 
Uremia 
Nutritional deficiencies 
Table 1. Factors that affect wound healing. 
In view of the large variety of factors that can be involved in impaired healing wounds, the 
types of chronic wounds are numerous. However, the most common chronic wounds are 
pressure ulcers, diabetic ulcers, and venous ulcers. Together, they constitute approximately 
70% of all chronic wounds (Eaglstein and Falanga 1997). 
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2.2 Pathophysiology of impaired wounds 
The differences in physiology and healing dynamics between acute and chronic wounds are 
numerous (Figure 1) (Schultz and Wysocki 2009). Excessive inflammation and abnormalities 
in cell-extracellular matrix interaction are considered important mechanisms responsible for 
the failure of chronic wounds to heal (Eming, Krieg et al. 2007; Menke, Ward et al. 2007; 
Schultz and Wysocki 2009). 
 
 
Fig. 1. Comparison of a chronic wound in which repair is arrested and an acute wound in 
which repair proceeds in an orderly, sequential fashion. Differences between these wounds 
are seen in clot formation, inflammation, capillary migration, granulation tissue, 
extracellular matrix, keratinocyte migration, scar formation, bacterial colonization/infection, 
and biofilm formation (Schultz and Wysocki 2009).   
Impaired wounds exhibit an out-of-control prolonged inflammatory response that is self-
sustaining (Menke, Ward et al. 2007). An over-abundant neutrophil infiltration is 
responsible for this chronic inflammation (Diegelmann 2003; Diegelmann and Evans 2004). 
Neutrophils release significant amounts of enzymes such as metalloproteinases (Yager, 
Zhang et al. 1996; Nwomeh, Liang et al. 1998; Nwomeh, Liang et al. 1999; Lobmann, 
Ambrosch et al. 2002), which are not balanced by their respective inhibitors. As a result, the 
balance between matrix degradation and synthesis shifts towards degradation (Bullen, 
Longaker et al. 1995). In addition, neutrophils release elastase, an enzyme that is capable to 
destroy growth factors such as PDGF and TGF-β (Yager, Zhang et al. 1996). This prolonged 
Copyright 2009 by the Wound Healing Society 
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inflammatory environment also contains excessive reactive oxygen species that further 
damage cells, growth factors and healing tissues (Wenk, Foitzik et al. 2001). Abnormalities 
in extracellular matrix - growth factor interactions characterize impaired wound healing 
(Schultz and Wysocki 2009). Impaired wounds are difficult to heal until the delayed 
inflammation is reduced and the interactions between extracellular matrix and growth 
factors are restored. Wound treatment strategies, with a focus on regulating these disrupted 
interactions, may benefit the treatment of impaired wound healing. 
3. ‘Standard’ management options for wounds 
The final goal of any wound management is to achieve wound healing. In the eyes of a cell 
biologist, these strategies might be seen as attempts to assist the injured tissue in recreating an 
extracellular matrix and cellular content, to enable tissue regeneration. In a somewhat 
simplistic view, most of the current routine clinical strategies to improve wound healing, 
therefore, can be classified into one or more of the categories that are depicted in Table 2. 
 
 TREATMENT / 
STRATEGY 
BENEFIT TO WOUND 
HEALING 
LITERATURE 
(REVIEWS) 
1. Debridement  
(e.g. surgical, enzymatic, 
chemical) 
Bring the wound edges into viable 
tissue in order to allow cells to 
deposit the right extracellular 
matrix needed for their migration 
and differentiation 
(Attinger and Bulan 
2001; Hess and Kirsner 
2003) 
2. Moisture management Create an environment that assists 
in propagating cell migration into 
the wound area 
(Okan, Woo et al. 2007; 
Korting, Schollmann et 
al. 2011) 
3. Exudate management 
(e.g. by the application of 
foams, sponges or 
vacuum therapy) 
Draining the wound fluid to clear 
extracellular matrix degrading 
enzymes and bacterial toxins  
(Vowden and Vowden 
2003) 
4. Local infection 
management 
Create a sterile environment by 
clearing the wound from bacteria 
and secreted harmful substances, 
followed by creating a bacterial 
balance 
(Fung, Chang et al. 2003) 
5. Inflammation 
management 
Reduce the severity and duration 
of the immune reaction, to limit 
the production of soluble growth 
factors by immune cells that 
attract infiltrating, scar tissue 
producing, fibroblasts 
(Nathan 2002; 
Diegelmann and Evans 
2004) 
6. Growth factor 
management 
Replenish the wound area, 
extracellular matrix and its 
cellular components with growth 
factors 
(Krishnamoorthy, 
Morris et al. 2001; 
Barrientos, Stojadinovic 
et al. 2008) 
Table 2. Cell biological effects of clinical treatment modalities 
 
Heparan Sulfate Proteoglycan Mimetics Promote Tissue Regeneration: An Overview 
 
75 
4. Advanced treatment options for wounds 
Healing-arrested (chronic) wounds seriously lower the patient’s quality of life and their 
treatments are extremely resource consuming. In the USA the costs related to chronic 
wounds are estimated over $25 billion a year (Fan, Tang et al. 2011). In the European Union 
the costs related to pressure ulcers and venous ulcers are estimated around €20 billion per 
year. The severity of the problem, likely accompanied by the substantial financial gain that 
can be envisioned, triggers the development of a great variety of advanced treatment 
options. Many are described in literature, although mostly with minimal of proof of efficacy. 
Also many reviews exist on this topic (recent examples are e.g. (Rizzi, Upton et al. 2010; Fan, 
Tang et al. 2011).  
In the context of this chapter, only a limited discussion will follow that covers the following 
‘state of art’ strategies: 
1. Gene therapy 
2. Platelet rich plasma therapy 
3. Stem cell therapy 
4. Biological dressings and skin substitutes  
4.1 Gene therapy 
Gene therapy clearly holds promise in the repair of soft tissue disorders like wounds 
(reviews on this topic e.g. Branski, Pereira et al. 2007; Eming, Krieg et al. 2007). Skin is easily 
accessible for genetic manipulations and has cellular constituents with a high turnover that 
can be an effective target for the transfer of genetic material. Especially a temporal delivery 
of growth factors by gene transfer may be helpful in transforming chronic wounds into 
healing wounds.  
July 2011, gene therapy trials are listed at www.clinicaltrials.gov concerning patients with 
diabetes-related, and lower limb ischemia-related ulcers. However, the application of 
genetic manipulation to the treatment of chronic wounds is still in its infancy. 
4.2 Platelet rich plasma therapy 
The alpha granules of platelets are rich in growth factors that are considered important for 
wound healing, amongst them EGF, FGF, PDGF, TGF-β and VEGF. Therefore, the use of 
platelet rich plasma is considered superior to any single growth factor application. Topical 
use of platelet rich plasma is described over 2 decades in several case series. E.g. following a 
weekly application to patients with cutaneous wounds of variable origin, Crovetti et al. 
(2004) described a complete response in 9 of 24 patients and a partial response in an 
additional 9 patients (Crovetti, Martinelli et al. 2004). Schade and Roukis (2008) reported 
beneficial effects of platelet-rich plasma to the healing of split-thickness skin grafts (Schade 
and Roukis 2008). Kazakos et al. compared the use of platelet rich plasma versus 
conventional therapy in 59 patients suffering from acute trauma wounds. And reported a 
beneficial effect on wound size reduction and pain perception over a three week period 
(Kazakos, Lyras et al. 2009).  Steed et al. (1992) performed a randomised controlled trial in 13 
diabetic foot patients and observed, over a period of 15 weeks, increased healing in the 
platelet rich plasma group (Steed, Goslen et al. 1992).  
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July 2011, platelet rich plasma trials are listed at www.clinicaltrials.gov concerning patients 
with burns, skin grafts, and leg ulcers. 
4.3 Stem cell therapy 
Literature on the use of bone marrow-derived stems cells, adipogenic stem cells and  
cutaneous mesenchymal stem cells, that are reported around the hair follicles, is manifold 
(reviews on this topic e.g. (Sellheyer and Krahl 2010; Wu, Zhao et al. 2010). At the preclinical 
level, evidence in wound areas is accumulating regarding the differentiation of bone 
marrow-derived stem cells into dermal fibroblasts, fibrocytes and endothelial progenitor 
cells. However, at the clinical level, reports of sufficient quality are scarce. Dash et al. (2009) 
reported beneficial effects on ulcer healing and ulcer pain of the addition of bone marrow-
derived mesenchymal stem cells to a total of 24 patients with lower limb non-healing ulcers 
that were randomly allocated to the placebo or stem cell therapy group (Dash, Dash et al. 
2009). Walther et al. (2011) reported a pilot on the intraarterial administration of bone 
marrow derived mononuclear cells to patients with critical ischemia in a phase II 
randomised-start open label study (Walter, Krankenberg et al. 2011). Forty patients enrolled 
over a period of 3 years and a significantly improved ulcer healing and reduction of rest 
pain were found in the bone marrow group. 
July 2011, over ten stem cell trials are listed at www.clinicaltrials.gov concerning patients 
with burn, pressure, diabetes-related and lower limb ischemia-related ulcers.  
4.4 Biological dressings and skin substitutes 
The complexity of the skin: its cellular constitution, extracellular matrix characteristics and 
the many growth factors involved in maintaining functional skin layers, let alone their 
involvement in wound healing (Table 3), largely determined research efforts.  
Reports on dermal replacement and dermal addition strategies are manifold (recent reviews 
on this topic e.g. (Rizzi, Upton et al. 2010; Fan, Tang et al. 2011)).  Briefly, research efforts to 
establish novel treatments can be categorized in tissue engineered skin based therapies, 
growth-factor based therapies, extracellular matrix based therapies and combinations 
thereof. 
Dermal replacements, e.g. to cover large ulcers or burn injuries, are described using 
autografts, allografts or tissue engineered skin substitutes. Over a dozen of tissue 
engineered dermal replacements are on the market (Rizzi, Upton et al. 2010). 
Dermal addition strategies are described using collagen, chondroitin-6-sulfate and 
hyaluronic acid. 
Growth factor addition into the wound bed aims to reestablish or accelerate the natural 
healing process of chronic and acute wounds. Predominantly via preclinical research efforts, 
with currently PDGF and bFGF on the clinical market  (Rizzi, Upton et al. 2010). 
Hodde and Johnson (2007) elaborate on the role of the extracellular matrix to stimulate, 
direct and coordinate healing by storing a variety of growth factors at physiological levels 
(Hodde and Johnson 2007). 
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Table 3. Major growth factors and cytokines that participate in wound healing with cell 
types and their respective roles in both acute and chronic wounds are listed (Barrientos, 
Stojadinovic et al. 2008). Reference numbers refer to their original publication. 
4.5 Concerns about biological products based treatment 
Although some of the new techniques mentioned above are promising in small-scale trials, 
only a minority are evidence based. Important issues that need to be addressed:   
- Lack of large double blinded randomised controlled preclinical trials.    
The current evidence for many biological products based treatment is generally based 
on non-randomised prospective trials, small-scale trials, or single case studies.  
- Lack of sufficient evidence of efficacy. 
The efficacy of most biological products is currently not approved in large trials. 
Copyright 2008 by the Wound Healing Society 
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- Lack of cost-effectiveness. 
As most biological products are expensive the lack of cost-effectiveness studies may 
limit their widespread application. 
- Confirmation of safety.  
Many sources of the biological products are from human or animal tissues, which hold 
the, theoretical, risk of transmitting infection and diseases. 
Both standard and advanced wound healing strategies frequently aim to recreate a bioactive 
extracellular matrix. In the remainder of this overview, the focus is on the constituents of the 
extracellular matrix that secures the stability of growth factors in the matrix. Their role in 
enabling tissue homeostasis and tissue regeneration is discussed. 
5. Tissue homeostasis and the extracellular matrix 
Proteoglycans consist of a core protein with one or more covalently linked 
glycosaminoglycan chains.  Glycosaminoglycans are long chain, high molecular weight 
carbohydrates. Some of these are sulfated (chondroitin sulfate, dermatan sulfate and 
heparan sulfate), other are non-sulfated (hyaluronic acid) (McGrath and Eady, 1997). When 
combined with water glycosaminoglycans form a gel and contribute to the viscoeleastic 
properties of connective tissue. In addition to this mechanical role, proteoglycans may also 
have regulatory roles of which heparan sulfate is a prominent example. 
Heparan sulfates are linear polysaccharides with variable degrees of sulfation, N-sulfation 
and N-acetylation (Dreyfuss, Regatieri et al. 2009) (Tumova, Woods et al. 2000). Heparan 
sulfates are widely spread throughout the animal kingdom ranging from invertebrates to 
mammals. In organs and tissues, they are a ubiquitous part of the extracellular matrix since 
many of the matrix scaffold proteins, such as collagens, fibronectin and laminin, possess 
heparan sulfate binding sites (Dreyfuss, Regatieri et al. 2009).  
A large variety of proteins can bind heparan sulfates. Amongst these are cell surface 
proteins, extracellular matrix proteins, growth factors, cytokines, chemokines and 
morphogens. Heparan sulfates protect these proteins from degradation and secure their 
presence in the extracellular matrix. Due to the ubiquitous nature of heparan sulfates, the 
large amount of proteins they sequester and their fine-tuning effect in growth factor 
bioavailability, heparan sulfates participate in many physiological activities (e.g. cell 
proliferation, -migration, -differentiation and cell - cell interaction). And, therefore, play a 
prominent role in enabling tissue homeostasis, the process in which the tissues and organs 
pursue a constant internal environment and cellular composition (Watt and Fujiwara 
2011). 
However, the tissues response to ‘stress’, with stress being any form of integrity disturbance 
such as injury, inflammation, overuse, auto-immune response, is in releasing cleavage 
enzymes that degrade the proteins and glycosaminoglycans of the extracellular matrix, 
including heparan sulfates. Through this degradation, the orchestrating role of heparan 
sulfate in growth factor and cytokine sequestration is lost which ends tissue homeostasis 
(Barritault, Garcia-Filipe et al. 2010).  
In wound healing, particularly in chronic wounds, dysregulation within the  extracellular 
matrix and between cells and the extracellular matrix has gained importance (Cook, Davies 
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et al. 2000) and do therapeutic initiatives to restore the defective extracellular matrix and to 
reposition heparan sulfates (Agren and Werthen 2007; Gandhi and Mancera 2010). 
6. ReGeneraTing Agents 
6.1 Structure of RGTA 
ReGeneraTing Agents (RGTAs) are synthetic heparan sulfate mimics, resistant to glycanase 
digestion (Figure 2) (Barbier-Chassefiere, Garcia-Filipe et al. 2009; Ikeda, Charef et al. 2011).  
 
 
Fig. 2. RGTA OTR4120 is a structural analogue of glycosaminoglycans. 
6.2 Working concept of RGTA / RGTA OTR4120 
In wound areas, RGTAs can replace heparan sulfates by binding the free heparan binding 
sites that become available following heparan sulfate degradation. This way, RGTAs can 
regulate the bioavailability of the large variety of, locally synthesized, heparin binding 
proteins which allow the cellular tissue components to re-unfold their natural mechanism to 
achieve wound regeneration. 
RGTA OTR4120 is a RGTA member specifically designed to treat chronic wounds and 
marketed as CACIPLIQ20® (OTR3, Paris, France). The affinity constant of RGTA OTR4120 
towards the vacant heparan sulfate binding sites of the extracellular matrix proteins allows a 
tight binding. This makes a short-term exposure to RGTA OTR4120 sufficient. Once RGTA 
OTR4120 is in place in the matrix scaffold, the growth factors, cytokines and other heparin 
binding signaling peptides can be repositioned through RGTA OTR4120 binding in this 
restored micro-environment. In this way, RGTA OTR4120 is thought to offer a matrix 
therapy that restores the natural cellular microenvironment. This allows the endogenous 
signaling of cell communications needed for tissue regeneration to resume their original 
function thereby halting the self-perpetuating cycles, particularly in impaired healing 
wounds (Figure 3). 
Copyright 2011 by OTR3, 
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Fig. 3. RGTA OTR4120, mode of action.  
6.3 Synthesis, dosing and timing 
RGTA OTR4120 is prepared as a 85kD molecular weight fraction from T40 dextran by 
carboxymethylation and O-sulfonation (Barbier-Chassefiere, 2009; Ikeda, Charef et al. 2011). 
RGTA OTR4120 was proven completely resistant to digestion with multiple 
endoglycanases: heparanase, chondroitinase, hyaluronidase, dextranase (Table 4) (Ikeda, 
Charef et al. 2011). 
Following a single i.v. injection in mice at a dose of 5 mg/kg the half life of unbound 
OTR4120 in plasma was less than 60 minutes. A i.p. bolus injection of 50 mg/kg in this same 
model created a peak plasma concentration of 88 µg/ml after 90 min (Charef, Papy-Garcia et 
al. 2010). A study on the acute and subacute toxicity, following i.p. administration, revealed 
no significant toxicological changes for doses up to 50 mg/kg (Charef, Tulliez et al. 2010). 
Injected doses used in a preclinical setting routinely are in the range of 1 – 2 mg/kg. 
When topically administered on dermal wounds, a bell-shaped dose effect-curve was found 
for RGTA OTR4120 with an optimal dose of 0.1 mg/ml. A similar dose was found when 
treating skull defects (Colombier, Lafont et al. 1999) and parodontitis (Lallam-Laroye, 
Escartin et al. 2006). 
RGTA OTR4120 is by itself a non acting molecule that enables the cascade of signals, that 
propagate wound regeneration, to resume with proper timing. However, the frequency of 
Copyright 2011 by OTR3, SAS 
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applications should be timed as the number of free heparan binding sites are limited in 
wound tissue. RGTA OTR4120 administration every 3 days is proven sufficient to maintain 
the healing effect in the early phases. Excess RGTA OTR4120 may compete with sites on the 
matrix-bound RGTA for heparan binding growth factors. In following phases of wound 
regeneration a weekly administration also proofed to be effective (Tong, Zbinden et al. 2008; 
Barbier-Chassefiere, Garcia-Filipe et al. 2009). No specific studies are reported to further 
optimize the timing of RGTA OTR4120 application.   
 
 
Table 4. Polysaccharide digestion by endoglycanases. HM4120 = RGTA OTR4120 
(Ikeda, Charef et al. 2011) 
6.4 Preclinical evidence for dermal RGTA OTR4120 actions 
Effects of RGTA OTR4120 administration on tissue regeneration at the preclinical level are 
numerous and reported in over 70 scientific reports in close to 10 animal species. Dermal 
effects of RGTA OTR4120 administration are described in necrotic skin ulcers in mice (Barbier-
Chassefiere, Garcia-Filipe et al. 2009), incisional dermal wounds in rats (Barritault, Garcia-
Filipe et al. 2010), second degree burns in rats (Garcia-Filipe, Barbier-Chassefiere et al. 2007) 
(Zakine, Barbier et al. 2011), a rat surgical excision model (Tong, Zbinden et al. 2008; Tong, Tuk 
et al. 2009; Tong, Tuk et al. 2011) and in rat dermal ischemia ulcers (Tong, Tuk et al. 2011). 
6.4.1 Necrotic skin ulcers 
Barbier-Chassefiere et al. (2009) determined the effects of RGTA OTR4120 in a necrotic skin 
ulcer model in mice following doxorubicin administration. In the short term, the necrotic 
surface area was found to be decreased by 40% with an almost 50% reduction in leukocyte 
count, as a measure for the strength of the inflammatory reaction. RGTA OTR4120 
administration increased type I and decreased type III collagen which restoring these values 
to those found in normal skin (Barbier-Chassefiere, Garcia-Filipe et al. 2009).  The results 
obtained from this ulcer model indicate that RGTA OTR4120 matrix therapy can initiate 
tissue regeneration. This finding illustrates that matrix contains the proper information to 
regenerate and confirms the central role for a good-quality extracellular matrix in tissue 
regeneration (Barbier-Chassefiere, Garcia-Filipe et al. 2009).  
Copyright 2010 Elsevier, Ltd.
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6.4.2 Anti scar effects of RGTA 
Barritault et al. (2010) described the effects of RGTA OTR4120 administration to a dermal 
incisional wound model in hairless rats (Barritault, Garcia-Filipe et al. 2010). Topical 
administration of RGTA OTR4120 to the incision at days 0, 3 and 6 revealed a scar free healing 
at day 10 whereas in the placebo control scar formation was clearly present (Figure 4). 
 
 
Fig. 4. Macroscopic view of the scar, treated or not treated with RGTA OTR4120 after skin 
incision. The incision is induced at day 0. RGTA OTR4120 treatment is by topical application 
(0.1 mg/ml), using a cotton swab, at day 0 before closure by suture and at days 3 and 6.  
a: untreated skin incision (saline) at day 0;  b: untreated skin incision (saline) at day 9;   
c: RGTA OTR4120 treated skin incision at day 0;  d: RGTA OTR4120 treated skin incision at 
day 9. (Barritault, Garcia-Filipe et al. 2010) 
Also severe dermal burns are characterized fibrosis and excessive scarring. On a cellular 
level aberrant proliferation, inflammation and a changed extracellular matrix architecture 
are important characteristics for dermal fibrosis. Especially the increased presence of type 
III collagen is thought to link to the extend of fibrosis (Ulrich, Noah et al. 2002). Ulrich et 
al. (2003) demonstrated a long term increased type III collagen in fibrous tissue (Ulrich, 
Noah et al. 2003). In this view, treatments that normalize type III collagen expression 
without compromising wound healing are of utmost importance. Garcia-Filipe et al. 
(2007) determined the effects of RGTA OTR4120 administration to a second degree 
experimental burn on the skin of a hairless rat (Garcia-Filipe, Barbier-Chassefiere et al. 
2007). They observed a profoundly improved fibrotic index: this is the ratio of type III 
collagen over type I collagen. Normalization of the type III collagen / type I collagen ratio 
also lasted at their final experimental endpoint at 10 months and was caused by a 
decreased type III collagen production and created a collagen balance that resembled 
normal skin (Figure 5).  
Copyright 2010 Elsevier Masson SAS. 
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Fig. 5. Effect of OTR4120 on the relative proportions of collagen I and collagen III in control 
skin and burn sites. Three experimental groups were studied: control (healthy skin from 
untreated rats), burn sites from untreated rats, and burn sites from rats treated with 
OTR4120. Figure shows the ratio of collagen III over collagen I (fibrotic index) computed 
using the data in Figures 1 (A,B). Differences compared with control were evaluated using 
Student’s paired t test; *p values < 0.05 were considered significant (Garcia-Filipe, Barbier-
Chassefiere et al. 2007). 
 
 
Fig. 6. Evolution of the mean number of keratinocyte layers. RGTA administration increases 
the mean number of keratinocyte layers between day 3 and day 7 (above) in comparison with 
the control group (below). At day 1 and day 2, this number was 0; on and after day 60, this 
number was 6. (Zakine, Barbier et al. 2011) 
Copyright 2011 by the American Society of Plastic Surgeons. 
Copyright 2006 Wiley Periodicals, Inc.
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A study by Zakine et al. (2011), using this same model, revealed an increased 
reepithelialisation together with an increased number of keratinocyte layers and blood vessels 
in the RGTA OTR4120 administered group at the early stages of tissue regeneration that 
returned to control levels after 1 month post wounding (Figure 6) (Zakine, Barbier et al. 2011).  
6.4.3 Full-thickness excisional wounds 
Tong et al. studied the effects of RGTA OTR4120 administration to rat full-thickness 
excisional wounds (Tong, Zbinden et al. 2008; Tong, Tuk et al. 2009). RGTA OTR4120 
administration to surgical wounds in rapid healing normal rats significantly improved 
wound regeneration. RGTA OTR4120 administration promotes epidermal proliferation, 
increased neodermal granulation tissue deposition, inflammation resolution, improved the 
vascular response to local heating (Figure 7a), improved collagen maturation and improved 
the wound breaking strength at all measurement times up to 3 months post wounding 
(Figure 7b) (Tong, Zbinden et al. 2008; Tong, Tuk et al. 2009).  
 
 
Fig. 7a. The wounded skin and normal skin vascular responses to local heating  
(44°C for 10 minutes), expressed as the percentages of the increase blood flow over baseline 
flow, measured by laser Doppler flow with local heat provocation on days 13, 20, and  
78 after wounding. Error bars represent the standard deviation. **p<0.01 and ***p < 0.001 
indicate the significant differences between treated groups and control groups.  
(Tong, Zbinden et al. 2008) 
6.4.4 Ischemia-reperfusion wounds 
Tong et al. (2011) also studied the effects of RGTA OTR4120 administration to ischemia-
reperfusion wounds (Tong, Tuk et al. 2011). Similar findings as for the excisional wounds were 
observed in a cutaneous ischemia-reperfusion model obtained by magnet clamping of a skin 
fold in the neck area of the animal although with a delayed timing due to the clearance of the 
necrotic tissue (Tong, Tuk et al. 2011). In addition, monocyte/macrophage staining and CD68 
detection on Western blots revealed that RGTA OTR4120 administration facilitated an 
Copyright 2008 by the Wound Healing Society
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inflammation controlled environment that progressed to the normal stages of wound 
healing. 
 
 
Fig. 7b. Wound strength measured as the ratio of the breaking strength of the wounded skin 
versus that of normal skin on days 14, 21, and 79 after wounding. Error bars represent the 
standard deviation. *p < 0.05 and ***p < 0.001 indicate the significant differences between 
treated groups and control groups (Tong, Zbinden et al. 2008; Tong, Tuk et al. 2009). 
In summary: the ability of RGTA OTR4120 administration to reduce inflammation; increase 
angiogenesis; improved healing quality, amongst others reflected by the recurrence of 
normal dermal collagen balance and an increased tissue breaking strength have now been 
demonstrated in multiple models (Alexakis, Guettoufi et al. 2001; Alexakis, Caruelle et al. 
2004; Alexakis, Mestries et al. 2004; Barbier-Chassefiere, Garcia-Filipe et al. 2009; Tong, Tuk 
et al. 2011). All are signs of matrix reconstruction to a formulation that more closely 
resembles normal matrix. Specifically, RGTA OTR4120 decreasing collagen III accumulation, 
will dramatically reduce the fibrosis that frequently accompanies wound healing. These 
promising preclinical findings warrant studies on human subjects. 
6.5 Clinical evidence 
The first scientific report on the clinical use of RGTA OTR4120 was a study by Chebbi et al. 
(2008) who described the effects of local RGTA OTR4120 administration for one month to 
patients with treatment-resistant corneal-ulcers and to patients with treatment-resistant 
corneal dystrophy (Chebbi, Kichenin et al. 2008). RGTA OTR4120 administration resulted in 
the majority of cases in the complete healing of the ulcer. The effect on the keratitis was 
moderate, however, a significant pain reduction was observed that highly improved the 
patient’s quality of life (Chebbi, Kichenin et al. 2008).  
In a within-subject study, Groah et al. (2011) demonstrated the effect of RGTA OTR4120 
administration in a patient population of largely persistent pressure ulcers and 
vascular/venous ulcers (Groah, Libin et al. 2011). The mean duration of the ulcers was 2.5 
Copyright 2008 by the Wound Healing Society
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years. RGTA OTR4120 was administered on the debrided wound, twice weekly for 5 
minutes each time. After 4 weeks both a significant reduction in the wound size as well as in 
the pain perception was found (Groah, Libin et al. 2011). 
Van Neck et al. (2011) described the complete healing following of recurrent scalp ulcers 
RGTA OTR4120 administration (Van Neck, Zuidema et al. 2011).  
RGTA OTR4120 also was administered to a 60-year old male patient with a complex medical 
history. He suffered from obesity (BMI 35), developed type II diabetic over a decade ago and 
was on insulin treatment. Furthermore, he was known with alcohol and nicotine abuse, 
heart failure, pacemaker, cardiac and vascular disease and kidney and liver failure. In 1992 
and 2002 he has had several toe amputations on both his feet likely caused by his poor 
cardiac and vascular condition. The patient had developed the diabetic pressure ulcer under 
investigation on the palmar side of his right foot over 8 months ago. So far, he had been 
unsuccessfully treated with a wide variety of wound dressings (foams, alginate, hydro 
colloids, silver dressings, foils, impregnated gauzes and collagen) all applied up to three 
times weekly if needed. At the start of the OTR4120 treatment the wound measured 2.5 cm2 
(Figure 8A). The wound displayed an almost immediate response to OTR4120 treatment  
 
Fig. 8. Diabetic foot of a 60 year old male patient in a state of non-healing for over 8 months. 
A) day 0, the start of the twice weekly RGTA OTR4120 topical application. At this stage the 
wound measured 2.5 cm2; B) day 7, healthy granulation tissue immediately formed 
following RGTA OTR4120 treatment; C) day 16; D) day 31, near to complete wound closure; 
E) day 46; F) day 56, long term closure control. The inner dimensions of the grey shaded 
square are 30x30mm. 
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(Figure 8B). Healthy granulation tissue formed and the wound closed in the 5th week of 
treatment (Figure 8C-E). Further documentation of the wound area proved it remained 
completely healed (Figure 8F).  
6.6 Future perspectives 
The findings presented support the use of RGTA OTR4120 (CACIPLIQ20®) in treating 
(chronic) wounds by means of restoring the damaged extracellular matrix.    
Research to reduce the complexity of the molecule, to facilitate its synthesis and to increase 
its effectiveness, is ongoing (Ikeda, Charef et al. 2011).  Also oral administration, as a patient 
friendly means of administration with a RGTA OTR4120 delivery to the side of injury via 
(micro)circulation, are tested (Charef, Papy-Garcia et al. 2010) 
7. Concluding remarks 
Matrix therapy restores the natural extracellular microenvironment which allows the local 
cascade of signals to resume in the proper time and order to trigger tissue regeneration. 
(Barbier-Chassefiere, Garcia-Filipe et al. 2009). Therefore, matrix therapy with engineered 
biopolymers such as RGTA OTR4120 is simpler and easier to use than cell or gene therapy 
and is a new alternative in regenerative medicine. 
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